Dyadic International, Inc. (NASDAQ:DYAI) Sees Large Decrease in Short Interest

Dyadic International, Inc. (NASDAQ:DYAI) was the target of a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 164,800 shares, a drop of 7.7% from the October 31st total of 178,600 shares. Based on an average daily trading volume, of 37,500 shares, the days-to-cover ratio is currently 4.4 days. Currently, 0.8% of the company’s shares are short sold.

Institutional Investors Weigh In On Dyadic International

An institutional investor recently raised its position in Dyadic International stock. Chapin Davis Inc. increased its holdings in shares of Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 847,301 shares of the biotechnology company’s stock after purchasing an additional 21,000 shares during the quarter. Chapin Davis Inc. owned approximately 2.90% of Dyadic International worth $1,254,000 at the end of the most recent reporting period. 27.95% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Dyadic International in a research report on Thursday, November 14th.

Dyadic International Stock Down 0.6 %

Shares of NASDAQ:DYAI traded down $0.01 during trading on Monday, reaching $1.70. 70,626 shares of the stock traded hands, compared to its average volume of 50,972. The stock has a market cap of $50.30 million, a P/E ratio of -7.43 and a beta of 0.72. The stock has a 50-day moving average of $1.21 and a two-hundred day moving average of $1.43. Dyadic International has a 52-week low of $0.93 and a 52-week high of $2.67. The company has a debt-to-equity ratio of 1.54, a quick ratio of 5.15 and a current ratio of 5.15.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.06. The firm had revenue of $1.96 million during the quarter, compared to analysts’ expectations of $1.05 million. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. During the same period in the previous year, the company earned ($0.06) earnings per share. As a group, sell-side analysts expect that Dyadic International will post -0.18 earnings per share for the current fiscal year.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.